Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central nervous process, conolidine modulates alternate molecular targets. A Science Developments review identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://davidv382jmp1.wikiexpression.com/user